Yale Medicine physicians are using robotic bronchoscopy instead of traditional bronchoscopy for lung cancer diagnosis. Robotic bronchoscopy allows them to better reach smaller parts of the lungs. During a robotic bronchoscopy, the doctor uses a controller at a console to operate a robotic arm, which then guides the bronchoscope’s thin, flexible tube through the airways.
In a study of more than 1,100 people with COVID-19 undergoing treatment for cancer, researchers found lower COVID-19 vaccination rates among patients with comorbidities, metastatic solid tumors or non-B-cell hematologic malignancies, and those living in areas with lower education attainment and higher levels of unemployment.
Galera Therapeutics Inc. presented a supplemental net treatment benefit analysis of phase III ROMAN results at the 10th European Congress on Head and Neck Oncology, which took place March 8-11.
In a phase II trial led by researchers from MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage, resectable non-small cell lung cancer.
A clinical study testing revumenib, a novel targeted treatment, found 40% of patients with acute leukemia had complete response and showed how the cancer cells resist the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
Researchers at UT Southwestern Medical Center have discovered how healthy bacteria can escape the intestine, travel to lymph nodes and cancerous tumors elsewhere in the body, and boost the effectiveness of certain immunotherapy drugs.
Data from the phase III DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, were published in The New England Journal of Medicine. Results from this study were previously presented at the European Society for Medical Oncology Congress in September 2022.
Patients with high-risk melanoma who received the immunotherapy drug Keytruda (pembrolizumab) both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
Positive high-level results from the ADAURA phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2 and 3a) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
Positive high-level results from a planned interim analysis of the AEGEAN phase III, placebo-controlled trial showed that treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage (2a-3b) non-small cell lung cancer.
